Last reviewed · How we verify
serum antiscorpion
serum antiscorpion is a Antivenom (polyclonal antiserum) Biologic drug developed by Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.. It is currently FDA-approved for Scorpion envenomation (systemic toxicity). Also known as: anti-Scorpion venom Serum.
Serum antiscorpion is a polyclonal antivenom that neutralizes scorpion venom toxins through specific antibody binding.
Serum antiscorpion is a protein-based intervention used to treat scorpion sting and scorpion envenomation, as indicated by ClinicalTrials.gov. It is a polyvalent antiscorpion serum, as shown in the randomized controlled trial "Randomized Controlled Trial to Evaluate Efficiency and Safety of the Polyvalent Antiscorpion Serum of Birme" (NCT00739440).
At a glance
| Generic name | serum antiscorpion |
|---|---|
| Also known as | anti-Scorpion venom Serum |
| Sponsor | Laboratorios de Biologicos y Reactivos de México, S.A. de C.V. |
| Drug class | Antivenom (polyclonal antiserum) |
| Target | Scorpion venom toxins (multiple epitopes) |
| Modality | Biologic |
| Therapeutic area | Toxicology / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
This biologic product contains immunoglobulins (antibodies) derived from animal serum that have been raised against scorpion venom antigens. Upon administration, these antibodies bind to and neutralize active venom components, preventing their pathophysiological effects on the nervous and cardiovascular systems. It is used as an acute treatment to counteract systemic envenomation.
Approved indications
- Scorpion envenomation (systemic toxicity)
Common side effects
- Serum sickness
- Hypersensitivity reaction
- Anaphylaxis
Key clinical trials
- Randomized Controlled Trial to Compare Two Anti-scorpion Serums (PHASE4)
- Compare Two Anti-Scorpion Venom Serum In Children (PHASE3)
- AScVS and/ or Prazosin for Scorpion Envenomation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- serum antiscorpion CI brief — competitive landscape report
- serum antiscorpion updates RSS · CI watch RSS
- Laboratorios de Biologicos y Reactivos de México, S.A. de C.V. portfolio CI
Frequently asked questions about serum antiscorpion
What is serum antiscorpion?
How does serum antiscorpion work?
What is serum antiscorpion used for?
Who makes serum antiscorpion?
Is serum antiscorpion also known as anything else?
What drug class is serum antiscorpion in?
What development phase is serum antiscorpion in?
What are the side effects of serum antiscorpion?
What does serum antiscorpion target?
Related
- Drug class: All Antivenom (polyclonal antiserum) drugs
- Target: All drugs targeting Scorpion venom toxins (multiple epitopes)
- Manufacturer: Laboratorios de Biologicos y Reactivos de México, S.A. de C.V. — full pipeline
- Therapeutic area: All drugs in Toxicology / Emergency Medicine
- Indication: Drugs for Scorpion envenomation (systemic toxicity)
- Also known as: anti-Scorpion venom Serum
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing